# Safety and Efficacy Study of CNOP Chemotherapy in Diffuse Large B Cell Lymphoma

> **NCT02595242** · PHASE1 · WITHDRAWN · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.**

## Conditions studied

- Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Vincristine
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT02595242
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-06
- **Primary completion:** 2016-12
- **Final completion:** 2017-06
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2017-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02595242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02595242, "Safety and Efficacy Study of CNOP Chemotherapy in Diffuse Large B Cell Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02595242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*